A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma.
Clin Lymphoma Myeloma Leuk
; 24(5): e191-e195.e6, 2024 May.
Article
de En
| MEDLINE
| ID: mdl-38365528
ABSTRACT
In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory follicular lymphoma patients. SCHOLAR-5 is an external control cohort designed to act as a comparator to ZUMA-5. Here, we present an updated comparative analysis of ZUMA-5 and SCHOLAR-5, using the 36-month follow-up data and the intent-to-treat population of ZUMA-5. Using propensity-score methods, 127 patients in ZUMA-5 were compared to 129 patients in SCHOLAR-5. At this extended follow-up, axi-cel continues to demonstrate clinically meaningful benefits in survival compared to historically available treatments in this population.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Produits biologiques
/
Lymphome folliculaire
Limites:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Langue:
En
Journal:
Clin Lymphoma Myeloma Leuk
/
Clin. lymphoma myeloma leuk. (Online)
/
Clinical lymphoma myeloma & leukemia (Online)
Sujet du journal:
NEOPLASIAS
Année:
2024
Type de document:
Article
Pays de publication:
États-Unis d'Amérique